{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:22:40Z","timestamp":1789564960886,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s13300-021-01118-7","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:02:58Z","timestamp":1628143378000},"page":"2485-2498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-082X","authenticated-orcid":false,"given":"Johannes J.","family":"Kovarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Kaltenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"2","key":"1118_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1152\/physrev.1977.57.2.313","volume":"57","author":"MJ Peach","year":"1977","unstructured":"Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57(2):313\u201370.","journal-title":"Physiol Rev"},{"issue":"8","key":"1118_CR2","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1073\/pnas.92.8.3521","volume":"92","author":"M Ito","year":"1995","unstructured":"Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA. 1995;92(8):3521\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1118_CR3","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/en.2003-0150","volume":"144","author":"JL Lavoie","year":"2003","unstructured":"Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system\u2014an endocrine and paracrine system. Endocrinology. 2003;144(6):2179\u201383.","journal-title":"Endocrinology"},{"issue":"8622","key":"1118_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(88)90843-4","volume":"2","author":"JE Heeg","year":"1988","unstructured":"Heeg JE, de Zeeuw D, de Jong PE. Antiproteinuric effect of ACE inhibitors. Lancet. 1988;2(8622):1251\u20132.","journal-title":"Lancet"},{"issue":"26","key":"1118_CR5","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJM198512263132601","volume":"313","author":"Y Taguma","year":"1985","unstructured":"Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313(26):1617\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"1118_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-136-8-200204160-00010","volume":"136","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136(8):604\u201315.","journal-title":"Ann Intern Med"},{"issue":"15","key":"1118_CR7","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1517\/14656566.2015.1079623","volume":"16","author":"DF Marquez","year":"2015","unstructured":"Marquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Expert Opin Pharmacother. 2015;16(15):2283\u201392.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1118_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1118_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, He D, Zhang W, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3\u20135: a network meta-analysis of randomised clinical trials. Drugs. 2020;80(8):797\u2013811.","journal-title":"Drugs"},{"issue":"5","key":"1118_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1118_CR11","doi-asserted-by":"publisher","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","volume":"10","author":"H Minakuchi","year":"2020","unstructured":"Minakuchi H, Wakino S, Urai H, et al. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial. Sci Rep. 2020;10(1):16626.","journal-title":"Sci Rep"},{"issue":"2","key":"1118_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96(2):302\u201319.","journal-title":"Kidney Int"},{"issue":"2","key":"1118_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000077396","volume":"24","author":"X Zhou","year":"2004","unstructured":"Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model. Am J Nephrol. 2004;24(2):242\u20139.","journal-title":"Am J Nephrol"},{"issue":"15","key":"1118_CR14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831\u20138.","journal-title":"Circulation"},{"issue":"3","key":"1118_CR15","first-page":"1339","volume":"8","author":"G Zhou","year":"2016","unstructured":"Zhou G, Johansson U, Peng XR, Bamberg K, Huang Y. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db\/db mice. Am J Transl Res. 2016;8(3):1339\u201354.","journal-title":"Am J Transl Res"},{"issue":"23","key":"1118_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1118_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4093\/dmj.2012.36.2.128","volume":"36","author":"JH Ahn","year":"2012","unstructured":"Ahn JH, Hong HC, Cho MJ, et al. Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab J. 2012;36(2):128\u201335.","journal-title":"Diabetes Metab J"},{"issue":"2","key":"1118_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db09-1218","volume":"59","author":"GY Oudit","year":"2010","unstructured":"Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59(2):529\u201338.","journal-title":"Diabetes"},{"issue":"1","key":"1118_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/01.HYP.38.1.90","volume":"38","author":"S Sasaki","year":"2001","unstructured":"Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, Oshima T. Effects of angiotensin-(1\u20137) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension. 2001;38(1):90\u20134.","journal-title":"Hypertension"},{"issue":"1","key":"1118_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/micc.12159","volume":"22","author":"KA Carver","year":"2015","unstructured":"Carver KA, Smith TL, Gallagher PE, Tallant EA. Angiotensin-(1\u20137) prevents angiotensin II-induced fibrosis in cremaster microvessels. Microcirculation. 2015;22(1):19\u201327.","journal-title":"Microcirculation"},{"issue":"6","key":"1118_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1042\/CS20120111","volume":"123","author":"D Zimmerman","year":"2012","unstructured":"Zimmerman D, Burns KD. Angiotensin-(1\u20137) in kidney disease: a review of the controversies. Clin Sci (Lond). 2012;123(6):333\u201346.","journal-title":"Clin Sci (Lond)"},{"key":"1118_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/414128","volume":"2012","author":"SV Pinheiro","year":"2012","unstructured":"Pinheiro SV, Simoes ESAC. Angiotensin converting enzyme 2, angiotensin-(1\u20137), and receptor MAS axis in the kidney. Int J Hypertens. 2012;2012: 414128.","journal-title":"Int J Hypertens"},{"issue":"2","key":"1118_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","volume":"17","author":"M Paz Ocaranza","year":"2020","unstructured":"Paz Ocaranza M, Riquelme JA, Garcia L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116\u201329.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1118_CR24","doi-asserted-by":"publisher","first-page":"33678","DOI":"10.1038\/srep33678","volume":"21","author":"O Domenig","year":"2016","unstructured":"Domenig O, Manzel A, Grobe N, et al. Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci Rep. 2016;21(6):33678.","journal-title":"Sci Rep"},{"issue":"4","key":"1118_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2006080872","volume":"18","author":"BA Perkins","year":"2007","unstructured":"Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18(4):1353\u201361.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1118_CR26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206\u201352.","journal-title":"Hypertension"},{"issue":"25","key":"1118_CR27","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1016\/j.jacc.2016.10.017","volume":"68","author":"N Pavo","year":"2016","unstructured":"Pavo N, Wurm R, Goliasch G, et al. Renin-angiotensin system fingerprints of heart failure with reduced ejection fraction. J Am Coll Cardiol. 2016;68(25):2912\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1118_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/clinchem\/hvaa001","volume":"66","author":"ZPM Guo","year":"2020","unstructured":"Guo ZPM, McWhinney BC. Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism. Clin Chem. 2020;66(3):483\u201392.","journal-title":"Clin Chem"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","volume":"76","author":"ZPM Guo","year":"2020","unstructured":"Guo ZPM, Cowley D, et al. Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin II ratio in patients with primary aldosteronism. Hypertension. 2020;76:488\u201396.","journal-title":"Hypertension"},{"key":"1118_CR30","unstructured":"Croghan CW, Egeghy PP. Methods of dealing with values below the limit of detection using SAS. https:\/\/analytics.ncsu.edu\/sesug\/2003\/SD08-Croghan.pdf."},{"issue":"17","key":"1118_CR31","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1289\/ehp.7199","volume":"112","author":"JH Lubin","year":"2004","unstructured":"Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect. 2004;112(17):1691\u20136.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"1118_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ndt\/gfu265","volume":"30","author":"JJ Kovarik","year":"2015","unstructured":"Kovarik JJ, Antlanger M, Domenig O, et al. Molecular regulation of the renin-angiotensin system in haemodialysis patients. Nephrol Dial Transplant. 2015;30(1):115\u201323.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1118_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.healun.2016.08.022","volume":"36","author":"JJ Kovarik","year":"2017","unstructured":"Kovarik JJ, Kopecky C, Antlanger M, et al. Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients. J Heart Lung Transplant. 2017;36(3):355\u201365.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"1118_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.kint.2019.04.024","volume":"96","author":"P Cassis","year":"2019","unstructured":"Cassis P, Locatelli M, Corna D, Villa S, Rottoli D, Cerullo D, et al. Addition of cyclic angiotensin-(1\u20137) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. Kidney Int. 2019;96(4):906\u201317.","journal-title":"Kidney Int"},{"issue":"2","key":"1118_CR35","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/HYPERTENSIONAHA.116.07088","volume":"68","author":"G Shefer","year":"2016","unstructured":"Shefer G, Marcus Y, Knoll E, Dolkart O, Foichtwanger S, Nevo N, et al. Angiotensin 1\u20137 is a negative modulator of aldosterone secretion in vitro and in vivo. Hypertension. 2016;68(2):378\u201384.","journal-title":"Hypertension"},{"issue":"3","key":"1118_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","volume":"52","author":"M Epstein","year":"2021","unstructured":"Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from hans selye to the present. Am J Nephrol. 2021;52(3):209\u201316.","journal-title":"Am J Nephrol"},{"issue":"8","key":"1118_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709\u201316.","journal-title":"Am J Hypertens"},{"issue":"6","key":"1118_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/jhh.2009.81","volume":"24","author":"A Sato","year":"2010","unstructured":"Sato A, Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens. 2010;24(6):387\u201394.","journal-title":"J Hum Hypertens"},{"issue":"10","key":"1118_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ki.2011.505","volume":"81","author":"L Shavit","year":"2012","unstructured":"Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int. 2012;81(10):955\u201368.","journal-title":"Kidney Int"},{"issue":"3","key":"1118_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000492622","volume":"48","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, et al. Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study. Am J Nephrol. 2018;48(3):172\u201380.","journal-title":"Am J Nephrol"},{"issue":"6","key":"1118_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/07853890.2017.1313447","volume":"49","author":"M Antlanger","year":"2017","unstructured":"Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med. 2017;49(6):525\u201333.","journal-title":"Ann Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01118-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01118-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T07:58:38Z","timestamp":1629791918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01118-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01118-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"29 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}